Monday, December 15, 2025

Latest

Psyched Wellness Sees Professor David Nutt Move From Advisory Role To Directorship

It appears that Professor David Nutt has a desire to become more involved with that of Psyched Wellness (CSE: PSYC). Currently the chair of the Scientific Advisory Board for Compass Pathways (NASDAQ: CMPS), Nutt has elected to step up from his role as an advisor to Psyched Wellness to that of a directorship.

Nutt is well versed in the area of psychopharmacology, which is the study of the effects of drugs on the brain. In layman terms, his focus is on how and why addictions can occur, as well as how treatments in both psychiatry and neurology work. Presently, he works as a psychiatrist as the Edmond J. Safra Chair of Neuropsychopharmacology at Imperial College London, within the Division of Brain Sciences.

Speaking specifically to his work, Nutt is well respected within the field, with his research having lead to over 500 original research papers. Furthermore, a comparable number of reviews and book chapters have been written by Nutt, along with eight government reports on drugs and 35 books. Not all of his writing has been directed to the medical community specifically, with one book, Drugs: Without the Hot Air, being written for consumption by the general public.

Past roles held by Nutt are rather impressive as well, with him having served as President of four separate medical councils: The European Brain Council, the European College of Neuropsychopharmacology, the British Association of Pharmacology, and the British Neuroscience Association. He’s also the founding chair of Drug Science, while holding visiting professorships at multiple universities.

“As a recent pioneer in the field of psychedelic medicine I have long been fascinated by the centuries-old use of Amanita Muscaria. When Psyched Wellness offered me the chance to bring this novel psychedelic mushroom into modern science and medicine, I jumped at it!”

Professor David Nutt

Psyched Wellness last traded at $0.13 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Soma Gold: Q3 Earnings Impacted By Labour Strike

Thesis Gold: The Multi-Billion Dollar Lawyers-Ranch PFS

Why Canada Has So Few Projects That Can Be Built Before 2030 | Dan Wilton – First Mining

Recommended

Steadright Locks Up Goundafa Polymetallic Mine Under Binding MOU

Emerita Resources Awards Contract For Pre-Feasibility Study On Iberian Belt West Project

Related News

Psyched Wellness Raises $6.6 Million In Bought Deal Financing

Psyched Wellness (CSE: PSYC) has closed its previously announced private placement. The company managed to...

Wednesday, February 17, 2021, 11:38:02 AM

Daily Dive: Shroom Stocks About To Fly? With Jeff Stevens, CEO Of Psyched Wellness

Today on The Daily Dive we have Jeff Stevens, CEO of Psyched Wellness (CSE: PSYC)....

Monday, November 9, 2020, 01:00:00 PM

Psyched Wellness Sees Amanita Muscaria Approved As Medicinal Organism By Health Canada

After more than a years worth of development work, Psyched Wellness (CSE: PSYC) this morning...

Wednesday, November 3, 2021, 08:10:25 AM

Psyched Wellness Completes Maximum Tolerated Dosage Study For Amanita Muscaria Extract AME-1

Psyched Wellness (CSE: PSYC) this morning issued a brief press release related to the ongoing...

Tuesday, March 2, 2021, 07:24:03 AM

Psyched Wellness Begins Pre-Clinical Trials Of Amanita Muscaria Mushroom

Psyched Wellness (CSE: PSYC) this morning announced that it has commenced its pre-clinical trials of...

Wednesday, December 23, 2020, 08:02:43 AM